Recent advances in melittin-based nanoparticles for antitumor treatment: from mechanisms to targeted delivery strategies

As a naturally occurring cytolytic peptide, melittin (MLT) not only exhibits a potent direct tumor cell-killing effect but also possesses various immunomodulatory functions. MLT shows minimal chances for developing resistance and has been recognized as a promising broad-spectrum antitumor drug becau...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of nanobiotechnology Jg. 21; H. 1; S. 454 - 22
Hauptverfasser: Yu, Xiang, Jia, Siyu, Yu, Shi, Chen, Yaohui, Zhang, Chengwei, Chen, Haidan, Dai, Yanfeng
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London BioMed Central 28.11.2023
BioMed Central Ltd
Springer Nature B.V
BMC
Schlagworte:
Allergic reactions
Angiogenesis
Antimicrobial peptides
Antimitotic agents
Antineoplastic agents
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Antitumor activity
Apoptosis
Biotechnology
Bladder cancer
Cancer therapies
Cell cycle
Cell death
Chemical properties
Chemistry
Chemistry and Materials Science
Coagulation
Colorectal cancer
Cyclin-dependent kinases
Cytolytic activity
Dosage and administration
Drug delivery
Drug delivery systems
Drug dosages
Drug resistance
Drugs
Health aspects
Humans
Hypersensitivity
Immunomodulation
Immunomodulators
Immunomodulatory
Kinases
Melitten - chemistry
Melitten - pharmacology
Melitten - therapeutic use
Melittin
Metastasis
Molecular Medicine
Molecular modelling
Multimechanism
Nanoparticles
Nanoparticles - chemistry
Nanotechnology
Neoplasms - drug therapy
Peptides
Peptides - therapeutic use
Pharmaceutical research
Proteins
Review
Side effects
Therapy
Toxicity
Tumor
Tumor necrosis factor-TNF
Tumors
Vascular endothelial growth factor
Vehicles
China
Tumor
Side effects
Melittin
Immunomodulatory
Multimechanism
ISSN:1477-3155, 1477-3155
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract As a naturally occurring cytolytic peptide, melittin (MLT) not only exhibits a potent direct tumor cell-killing effect but also possesses various immunomodulatory functions. MLT shows minimal chances for developing resistance and has been recognized as a promising broad-spectrum antitumor drug because of this unique dual mechanism of action. However, MLT still displays obvious toxic side effects during treatment, such as nonspecific cytolytic activity, hemolytic toxicity, coagulation disorders, and allergic reactions, seriously hampering its broad clinical applications. With thorough research on antitumor mechanisms and the rapid development of nanotechnology, significant effort has been devoted to shielding against toxicity and achieving tumor-directed drug delivery to improve the therapeutic efficacy of MLT. Herein, we mainly summarize the potential antitumor mechanisms of MLT and recent progress in the targeted delivery strategies for tumor therapy, such as passive targeting, active targeting and stimulus-responsive targeting. Additionally, we also highlight the prospects and challenges of realizing the full potential of MLT in the field of tumor therapy. By exploring the antitumor molecular mechanisms and delivery strategies of MLT, this comprehensive review may inspire new ideas for tumor multimechanism synergistic therapy.
AbstractList As a naturally occurring cytolytic peptide, melittin (MLT) not only exhibits a potent direct tumor cell-killing effect but also possesses various immunomodulatory functions. MLT shows minimal chances for developing resistance and has been recognized as a promising broad-spectrum antitumor drug because of this unique dual mechanism of action. However, MLT still displays obvious toxic side effects during treatment, such as nonspecific cytolytic activity, hemolytic toxicity, coagulation disorders, and allergic reactions, seriously hampering its broad clinical applications. With thorough research on antitumor mechanisms and the rapid development of nanotechnology, significant effort has been devoted to shielding against toxicity and achieving tumor-directed drug delivery to improve the therapeutic efficacy of MLT. Herein, we mainly summarize the potential antitumor mechanisms of MLT and recent progress in the targeted delivery strategies for tumor therapy, such as passive targeting, active targeting and stimulus-responsive targeting. Additionally, we also highlight the prospects and challenges of realizing the full potential of MLT in the field of tumor therapy. By exploring the antitumor molecular mechanisms and delivery strategies of MLT, this comprehensive review may inspire new ideas for tumor multimechanism synergistic therapy.
As a naturally occurring cytolytic peptide, melittin (MLT) not only exhibits a potent direct tumor cell-killing effect but also possesses various immunomodulatory functions. MLT shows minimal chances for developing resistance and has been recognized as a promising broad-spectrum antitumor drug because of this unique dual mechanism of action. However, MLT still displays obvious toxic side effects during treatment, such as nonspecific cytolytic activity, hemolytic toxicity, coagulation disorders, and allergic reactions, seriously hampering its broad clinical applications. With thorough research on antitumor mechanisms and the rapid development of nanotechnology, significant effort has been devoted to shielding against toxicity and achieving tumor-directed drug delivery to improve the therapeutic efficacy of MLT. Herein, we mainly summarize the potential antitumor mechanisms of MLT and recent progress in the targeted delivery strategies for tumor therapy, such as passive targeting, active targeting and stimulus-responsive targeting. Additionally, we also highlight the prospects and challenges of realizing the full potential of MLT in the field of tumor therapy. By exploring the antitumor molecular mechanisms and delivery strategies of MLT, this comprehensive review may inspire new ideas for tumor multimechanism synergistic therapy. Keywords: Melittin, Immunomodulatory, Side effects, Tumor, Multimechanism
As a naturally occurring cytolytic peptide, melittin (MLT) not only exhibits a potent direct tumor cell-killing effect but also possesses various immunomodulatory functions. MLT shows minimal chances for developing resistance and has been recognized as a promising broad-spectrum antitumor drug because of this unique dual mechanism of action. However, MLT still displays obvious toxic side effects during treatment, such as nonspecific cytolytic activity, hemolytic toxicity, coagulation disorders, and allergic reactions, seriously hampering its broad clinical applications. With thorough research on antitumor mechanisms and the rapid development of nanotechnology, significant effort has been devoted to shielding against toxicity and achieving tumor-directed drug delivery to improve the therapeutic efficacy of MLT. Herein, we mainly summarize the potential antitumor mechanisms of MLT and recent progress in the targeted delivery strategies for tumor therapy, such as passive targeting, active targeting and stimulus-responsive targeting. Additionally, we also highlight the prospects and challenges of realizing the full potential of MLT in the field of tumor therapy. By exploring the antitumor molecular mechanisms and delivery strategies of MLT, this comprehensive review may inspire new ideas for tumor multimechanism synergistic therapy.
Abstract As a naturally occurring cytolytic peptide, melittin (MLT) not only exhibits a potent direct tumor cell-killing effect but also possesses various immunomodulatory functions. MLT shows minimal chances for developing resistance and has been recognized as a promising broad-spectrum antitumor drug because of this unique dual mechanism of action. However, MLT still displays obvious toxic side effects during treatment, such as nonspecific cytolytic activity, hemolytic toxicity, coagulation disorders, and allergic reactions, seriously hampering its broad clinical applications. With thorough research on antitumor mechanisms and the rapid development of nanotechnology, significant effort has been devoted to shielding against toxicity and achieving tumor-directed drug delivery to improve the therapeutic efficacy of MLT. Herein, we mainly summarize the potential antitumor mechanisms of MLT and recent progress in the targeted delivery strategies for tumor therapy, such as passive targeting, active targeting and stimulus-responsive targeting. Additionally, we also highlight the prospects and challenges of realizing the full potential of MLT in the field of tumor therapy. By exploring the antitumor molecular mechanisms and delivery strategies of MLT, this comprehensive review may inspire new ideas for tumor multimechanism synergistic therapy.
As a naturally occurring cytolytic peptide, melittin (MLT) not only exhibits a potent direct tumor cell-killing effect but also possesses various immunomodulatory functions. MLT shows minimal chances for developing resistance and has been recognized as a promising broad-spectrum antitumor drug because of this unique dual mechanism of action. However, MLT still displays obvious toxic side effects during treatment, such as nonspecific cytolytic activity, hemolytic toxicity, coagulation disorders, and allergic reactions, seriously hampering its broad clinical applications. With thorough research on antitumor mechanisms and the rapid development of nanotechnology, significant effort has been devoted to shielding against toxicity and achieving tumor-directed drug delivery to improve the therapeutic efficacy of MLT. Herein, we mainly summarize the potential antitumor mechanisms of MLT and recent progress in the targeted delivery strategies for tumor therapy, such as passive targeting, active targeting and stimulus-responsive targeting. Additionally, we also highlight the prospects and challenges of realizing the full potential of MLT in the field of tumor therapy. By exploring the antitumor molecular mechanisms and delivery strategies of MLT, this comprehensive review may inspire new ideas for tumor multimechanism synergistic therapy.As a naturally occurring cytolytic peptide, melittin (MLT) not only exhibits a potent direct tumor cell-killing effect but also possesses various immunomodulatory functions. MLT shows minimal chances for developing resistance and has been recognized as a promising broad-spectrum antitumor drug because of this unique dual mechanism of action. However, MLT still displays obvious toxic side effects during treatment, such as nonspecific cytolytic activity, hemolytic toxicity, coagulation disorders, and allergic reactions, seriously hampering its broad clinical applications. With thorough research on antitumor mechanisms and the rapid development of nanotechnology, significant effort has been devoted to shielding against toxicity and achieving tumor-directed drug delivery to improve the therapeutic efficacy of MLT. Herein, we mainly summarize the potential antitumor mechanisms of MLT and recent progress in the targeted delivery strategies for tumor therapy, such as passive targeting, active targeting and stimulus-responsive targeting. Additionally, we also highlight the prospects and challenges of realizing the full potential of MLT in the field of tumor therapy. By exploring the antitumor molecular mechanisms and delivery strategies of MLT, this comprehensive review may inspire new ideas for tumor multimechanism synergistic therapy.
ArticleNumber 454
Audience Academic
Author Dai, Yanfeng
Yu, Xiang
Jia, Siyu
Yu, Shi
Chen, Yaohui
Zhang, Chengwei
Chen, Haidan
Author_xml – sequence: 1
  givenname: Xiang
  surname: Yu
  fullname: Yu, Xiang
  email: yuxiangwl2008@sina.com
  organization: State Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Key Laboratory of Biomedical Engineering of Hainan Province, One Health Institute, Hainan University
– sequence: 2
  givenname: Siyu
  surname: Jia
  fullname: Jia, Siyu
  organization: Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, The First College of Clinical Medical Science, China Three Gorges University
– sequence: 3
  givenname: Shi
  surname: Yu
  fullname: Yu, Shi
  organization: Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University
– sequence: 4
  givenname: Yaohui
  surname: Chen
  fullname: Chen, Yaohui
  organization: Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University
– sequence: 5
  givenname: Chengwei
  surname: Zhang
  fullname: Zhang, Chengwei
  organization: Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University
– sequence: 6
  givenname: Haidan
  surname: Chen
  fullname: Chen, Haidan
  email: wenquanchd@sina.com
  organization: The First College of Clinical Medical Science, China Three Gorges University
– sequence: 7
  givenname: Yanfeng
  surname: Dai
  fullname: Dai, Yanfeng
  email: daiyanfeng1216@163.com
  organization: State Key Laboratory of Digital Medical Engineering, School of Biomedical Engineering, Hainan University, Key Laboratory of Biomedical Engineering of Hainan Province, One Health Institute, Hainan University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38017537$$D View this record in MEDLINE/PubMed
BookMark eNp9kktr3DAUhU1JaR7tH-iiGLppF5NasjTSdBNC6CMQKKTtWlzLV46CLaWSJiT_vncykyYTSjC2hfSdY9_D2a92QgxYVW9Zc8iYnn_KjC8kmzW8pZvTU7yo9phQatYyKXcerXer_ZwvG6IEF6-q3VY3TMlW7VU352gxlBr6awgWc-1DPeHoS_Fh1kHGvg4Q4hWk4u1I5y6mGkLxZTnRqiSEMpHB59qlOJHUXkDwecp1iXWBNGAhi54crzHd1rkkKDh4zK-rlw7GjG8274Pq99cvv06-z85-fDs9OT6b2bngZaZdy3uhJTi3kK21QtpOuE6olv6_V1KhbjWdOYDW9YCNBQBkoulaZZGwg-p07dtHuDRXyU-Qbk0Eb-42YhrMZjYjHbBFJ5Fr1gnbS60bbZnUQjGBjHHyOlp7XS27CftVcAnGLdPtk-AvzBCvDWvmWiomyeHDxiHFP0vMxUw-WxxHCBiX2XC9kFzqhZ4T-v4JehmXKVBWhi8azlrOtHigBqAJfHCRPmxXpuZYKSEbPVcNUYf_oejqcfKWWuU87W8JPm4JiCl4UwZY5mxOf55vs-8ep_IvjvuSEaDXgE0x54TOWF-g-LgKyY-Ujln12az7bKjP5q7PZjUefyK9d39W1K5FmeAwYHpI7hnVX1iTB_w
CitedBy_id crossref_primary_10_1186_s11671_025_04322_7
crossref_primary_10_1007_s12035_025_04808_6
crossref_primary_10_1016_j_jconrel_2024_08_047
crossref_primary_10_1007_s10989_024_10600_2
crossref_primary_10_1186_s12967_025_06321_9
crossref_primary_10_1016_j_biopha_2024_117118
crossref_primary_10_3390_ijms26136102
crossref_primary_10_1186_s12951_024_02460_1
crossref_primary_10_3390_cancers17142331
crossref_primary_10_1007_s12602_024_10318_z
crossref_primary_10_3389_fimmu_2025_1652166
crossref_primary_10_1016_j_jddst_2025_106811
crossref_primary_10_3390_toxins17080371
crossref_primary_10_1016_j_colsurfb_2025_114512
crossref_primary_10_1007_s43939_025_00275_x
crossref_primary_10_1186_s12951_024_02694_z
crossref_primary_10_1111_cns_14715
crossref_primary_10_1002_adfm_202503374
crossref_primary_10_1016_j_phrs_2024_107430
crossref_primary_10_1021_acsami_5c09472
crossref_primary_10_3389_fphar_2024_1412245
crossref_primary_10_3389_fimmu_2025_1628014
crossref_primary_10_1007_s10637_024_01453_z
crossref_primary_10_1016_j_biopha_2024_117385
crossref_primary_10_1080_09205063_2025_2540362
crossref_primary_10_1016_j_toxicon_2025_108555
crossref_primary_10_1016_j_nano_2024_102796
crossref_primary_10_1080_20415990_2025_2484170
crossref_primary_10_3389_fmicb_2024_1419917
crossref_primary_10_3390_pharmaceutics17081019
crossref_primary_10_1016_j_micres_2024_127822
crossref_primary_10_3390_biomedicines13061415
crossref_primary_10_1039_D5MA00552C
Cites_doi 10.1016/j.clinthera.2016.03.026
10.1080/03639045.2019.1569029
10.1177/1534735420944476
10.7150/thno.25608
10.3390/toxins12020066
10.1007/s11095-007-9246-z
10.1007/s11095-016-1959-4
10.1113/JP275175
10.1039/D3RA00866E
10.1002/wnan.1332
10.1038/cdd.2016.35
10.3390/ijms20061508
10.1038/cddis.2017.390
10.1016/j.aller.2017.05.003
10.3389/fnmol.2022.1033159
10.1007/s12264-012-1213-y
10.1080/14756366.2022.2036985
10.1016/j.colsurfb.2022.112384
10.1016/j.aspen.2017.03.023
10.1021/acscentsci.0c00506
10.1016/j.molstruc.2022.134160
10.1039/C9NR01820D
10.1021/np300446c
10.1038/s41467-019-08538-x
10.1007/s11064-008-9689-6
10.1080/19768354.2022.2099971
10.3831/KPI.2015.18.031
10.1371/journal.pone.0224028
10.7150/ijbs.64654
10.1021/acsami.1c17618
10.3390/molecules27051653
10.1016/j.addr.2022.114467
10.1016/j.jconrel.2023.02.020
10.1016/S0041-0101(96)00078-5
10.1186/s12906-023-03897-x
10.1016/j.toxicon.2015.12.005
10.1016/j.toxicon.2010.07.005
10.3390/biom8030077
10.1016/j.ijpharm.2009.12.022
10.1080/10717544.2022.2072544
10.3892/ijo.2015.3078
10.1002/ctm2.727
10.1021/jacs.7b09224
10.1016/j.biopha.2023.114789
10.1021/acsami.0c00303
10.1186/s12951-022-01355-3
10.1038/s41586-020-2071-9
10.1186/s40425-019-0610-4
10.2147/IJN.S243223
10.1038/s41698-020-00129-0
10.18632/oncotarget.18627
10.1186/s12951-023-02026-7
10.1038/nrd3053
10.3390/ijms24098388
10.3390/toxins14070460
10.1007/s13346-022-01206-6
10.1002/adma.202002380
10.3390/antibiotics10121503
10.3390/toxins11050239
10.1074/jbc.M408881200
10.34133/research.0052
10.1021/acsnano.9b04181
10.3390/toxins14070428
10.1016/j.apsb.2021.07.020
10.1080/10715762.2022.2131551
10.1002/adhm.201800380
10.1021/acsami.7b18809
10.3390/molecules28031087
10.1002/btm2.10482
10.1371/journal.pone.0158235
10.1021/nn400683s
10.7554/eLife.47946
10.1016/j.jconrel.2023.03.004
10.1016/j.bioorg.2021.105329
10.3322/caac.21660
10.1186/s12951-023-01990-4
10.1007/978-1-4939-6737-7_31
10.1016/j.jconrel.2010.07.116
10.1007/s00709-013-0489-8
10.1007/s40544-022-0710-x
10.1038/nature10155
10.1016/j.redox.2022.102317
10.1016/j.jconrel.2022.08.001
10.1007/s00424-017-2065-0
10.1016/j.jconrel.2019.07.004
10.1111/febs.14186
10.1016/j.trecan.2022.07.008
10.3389/fonc.2020.563938
10.1021/acsami.1c14285
10.3390/biom10020247
10.1021/acsami.1c03640
10.1002/advs.202204184
10.5114/ada.2017.67082
10.1186/s12967-016-0910-0
10.1073/pnas.1307010110
10.1002/chem.201406510
10.1021/acs.bioconjchem.8b00352
10.1002/advs.201901866
10.1136/jitc-2020-001966
10.1002/hep.22240
10.3390/toxins7020423
10.1038/s41586-020-2079-1
10.1016/j.bcp.2006.01.012
10.31557/APJCP.2018.19.12.3427
10.1681/ASN.2018010039
10.1021/acs.biomac.9b01416
10.3390/cancers13020274
10.1186/s12974-022-02547-2
10.3390/nano12162851
10.3389/fimmu.2023.1178776
10.1016/j.msec.2021.112258
10.1021/acs.nanolett.8b01236
10.1126/sciadv.abc7828
10.3390/ijms23063094
10.3390/molecules21050616
10.1016/j.jconrel.2021.01.015
10.1038/s41467-020-14906-9
10.3389/fphar.2022.1001553
10.1371/journal.pone.0069380
10.1007/s12264-011-1018-4
10.7150/thno.51988
10.1039/D2CS00454B
10.3390/ijms22020738
10.2174/1871520620666200211091451
10.3390/pharmaceutics15051407
10.1016/j.canlet.2022.215615
10.1016/j.biomaterials.2021.121076
10.1021/acsnano.2c05379
10.1111/jphp.13158
10.1016/j.canlet.2017.05.010
10.1016/0167-4838(93)90024-L
10.3390/toxins12090582
10.1186/s12951-022-01536-0
10.1002/adhm.202301087
10.3390/toxins7041126
10.1080/03639045.2018.1427760
10.1016/j.jconrel.2020.04.019
10.2147/JHC.S355027
10.1016/j.cis.2020.102118
10.1021/nn5070259
10.1016/j.addr.2020.02.004
ContentType Journal Article
Copyright The Author(s) 2023
2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2023
– notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
ISR
3V.
7QO
7TB
7X7
7XB
88E
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABJCF
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
CCPQU
COVID
D1I
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
KB.
LK8
M0S
M1P
M7P
P64
PDBOC
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12951-023-02223-4
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Biotechnology Research Abstracts
Mechanical & Transportation Engineering Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
Materials Science & Engineering Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest SciTech Premium Collection Natural Science Collection Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
ProQuest One
Coronavirus Research Database
ProQuest Materials Science Collection
ProQuest Central Korea
Engineering Research Database
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Materials Science Database
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
Biotechnology and BioEngineering Abstracts
Materials Science Collection
Proquest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
Mechanical & Transportation Engineering Abstracts
ProQuest Central Essentials
Materials Science Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
Materials Science Database
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Materials Science Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Materials Science & Engineering Collection
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database



MEDLINE
MEDLINE - Academic


CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
Chemistry
EISSN 1477-3155
EndPage 22
ExternalDocumentID oai_doaj_org_article_5fa19b5e281b4cd58808c1584714e112
PMC10685715
A774508670
38017537
10_1186_s12951_023_02223_4
Genre Journal Article
Review
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: Yichang Science and Technology Program
  grantid: A19-301-12
– fundername: National Natural Science Foundation Program of China
  grantid: 82102206; 32201131
– fundername: Natural Science Foundation of Hubei Province
  grantid: 2020CFB371
– fundername: National Natural Science Foundation Program of China
  grantid: 82102206
– fundername: National Natural Science Foundation Program of China
  grantid: 32201131
– fundername: ;
  grantid: 82102206; 32201131
– fundername: ;
  grantid: A19-301-12
– fundername: ;
  grantid: 2020CFB371
GroupedDBID ---
0R~
29L
2WC
53G
5VS
7X7
88E
8FE
8FG
8FH
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABDBF
ABJCF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADDVE
ADMLS
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BBNVY
BCNDV
BENPR
BFQNJ
BGLVJ
BHPHI
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
D1I
DIK
DU5
E3Z
EBD
EBLON
EBS
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
I-F
IAO
IHR
INH
INR
ISR
ITC
ITG
ITH
KB.
KQ8
LK8
M1P
M48
M7P
MM.
M~E
O5R
O5S
OK1
OVT
P2P
PDBOC
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
RVI
SCM
SOJ
SV3
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
AAYXX
AFFHD
CITATION
-A0
3V.
ACRMQ
ADINQ
ALIPV
C24
CGR
CUY
CVF
ECM
EIF
FRP
NPM
7QO
7TB
7XB
8FD
8FK
AZQEC
COVID
DWQXO
FR3
GNUQQ
K9.
P64
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c642t-8f32d485aff953cc45cb4fb473753d757e838ff9faa3fdae0caaae140b37ce473
IEDL.DBID M7P
ISICitedReferencesCount 38
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001109968900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1477-3155
IngestDate Fri Oct 03 12:45:04 EDT 2025
Tue Nov 04 02:06:33 EST 2025
Thu Oct 02 06:10:48 EDT 2025
Sat Oct 18 23:55:15 EDT 2025
Sat Nov 29 14:18:36 EST 2025
Tue Nov 04 18:30:30 EST 2025
Wed Nov 26 11:12:27 EST 2025
Wed Feb 19 02:07:04 EST 2025
Sat Nov 29 02:43:16 EST 2025
Tue Nov 18 20:47:26 EST 2025
Sat Sep 06 07:35:11 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Tumor
Side effects
Melittin
Immunomodulatory
Multimechanism
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c642t-8f32d485aff953cc45cb4fb473753d757e838ff9faa3fdae0caaae140b37ce473
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink https://www.proquest.com/docview/2902132184?pq-origsite=%requestingapplication%
PMID 38017537
PQID 2902132184
PQPubID 44676
PageCount 22
ParticipantIDs doaj_primary_oai_doaj_org_article_5fa19b5e281b4cd58808c1584714e112
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10685715
proquest_miscellaneous_2895258986
proquest_journals_2902132184
gale_infotracmisc_A774508670
gale_infotracacademiconefile_A774508670
gale_incontextgauss_ISR_A774508670
pubmed_primary_38017537
crossref_citationtrail_10_1186_s12951_023_02223_4
crossref_primary_10_1186_s12951_023_02223_4
springer_journals_10_1186_s12951_023_02223_4
PublicationCentury 2000
PublicationDate 2023-11-28
PublicationDateYYYYMMDD 2023-11-28
PublicationDate_xml – month: 11
  year: 2023
  text: 2023-11-28
  day: 28
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Journal of nanobiotechnology
PublicationTitleAbbrev J Nanobiotechnol
PublicationTitleAlternate J Nanobiotechnology
PublicationYear 2023
Publisher BioMed Central
BioMed Central Ltd
Springer Nature B.V
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: Springer Nature B.V
– name: BMC
References C Tipgomut (2223_CR13) 2018; 19
UA Fahmy (2223_CR15) 2022; 29
M Moreno (2223_CR25) 2015; 7
M Liu (2223_CR26) 2016; 14
R Tiwari (2223_CR59) 2022; 12
J Zhou (2223_CR4) 2021; 13
G Sharma (2223_CR98) 2010; 147
J Zugazagoitia (2223_CR2) 2016; 38
A Belluati (2223_CR100) 2020; 21
G Yu (2223_CR93) 2017; 139
NM El Bakary (2223_CR32) 2020; 19
F Martín-Sánchez (2223_CR40) 2017; 8
T Wang (2223_CR129) 2023; 13
M Ceremuga (2223_CR22) 2020; 10
S Maher (2223_CR134) 2010; 387
Y Wang (2223_CR80) 2023; 11
S Liu (2223_CR34) 2008; 47
A Peña-Blanco (2223_CR21) 2018; 285
C Lee (2223_CR117) 2019; 7
Q Sun (2223_CR137) 2023; 12
H Cabral (2223_CR106) 2015; 9
FD Moghaddam (2223_CR19) 2020; 20
Y Zhou (2223_CR7) 2021; 9
JM Shin (2223_CR31) 2013; 8
CL Yu (2223_CR20) 2022; 9
MH Periayah (2223_CR73) 2017; 11
G Lee (2223_CR83) 2016; 21
H Qiao (2223_CR144) 2018; 10
SE Blondelle (2223_CR71) 1993; 1202
Z Zhang (2223_CR37) 2020; 579
J Wu (2223_CR43) 2020; 6
D Lu (2223_CR92) 2020; 6
R Schreiber (2223_CR51) 2019; 30
H Wang (2223_CR99) 2019; 11
H Qiao (2223_CR109) 2022; 20
J Maitip (2223_CR149) 2021; 10
R Ye (2223_CR128) 2021; 13
D Wang (2223_CR112) 2015; 47
X Yu (2223_CR56) 2019; 10
C Soliman (2223_CR24) 2019; 14
D Antolín-Amérigo (2223_CR85) 2018; 46
K Černe (2223_CR65) 2013; 250
M Sun (2223_CR14) 2023; 15
C Duffy (2223_CR115) 2020; 4
Y Xu (2223_CR97) 2020; 12
J Li (2223_CR45) 2020; 32
H Xiao (2223_CR127) 2022; 12
F Salimian (2223_CR35) 2022; 24
Y Lv (2223_CR69) 2022; 14
A Oddo (2223_CR70) 2017; 1548
H Koide (2223_CR148) 2023; 355
X Yu (2223_CR57) 2020; 11
M Prado (2223_CR81) 2010; 56
LA Clifton (2223_CR62) 2020; 277
EC Mingomataj (2223_CR75) 2012; 22
GH Mansour (2223_CR12) 2021; 116
C Yaacoub (2223_CR78) 2022; 27
J Lee (2223_CR79) 2017; 20
F Simões (2223_CR52) 2018; 470
A Kołaczek (2223_CR82) 2017; 34
CM Lee (2223_CR141) 2019; 20
S Ouyang (2223_CR48) 2022; 52
H Zolfagharian (2223_CR74) 2015; 18
K Daniluk (2223_CR110) 2023; 24
J Ding (2223_CR86) 2011; 27
BF Grześkowiak (2223_CR91) 2021; 22
PC Chiou (2223_CR61) 2022; 213
C Jeong (2223_CR114) 2023; 14
M Shahriari (2223_CR131) 2019; 308
J Li (2223_CR142) 2020; 15
P Shi (2223_CR16) 2022; 13
MM Rocha (2223_CR28) 2022; 28
EA Gentile (2223_CR95) 2019; 71
A Aufschnaiter (2223_CR33) 2020; 12
T Yamazaki (2223_CR44) 2016; 23
NY Kwon (2223_CR5) 2022; 14
R Yan (2223_CR23) 2022; 534
S Movassaghian (2223_CR96) 2015; 7
A Tuerkova (2223_CR63) 2020; 9
J Yin (2223_CR50) 2023; 52
IH Han (2223_CR55) 2022; 23
X Liu (2223_CR136) 2023; 15
H Liu (2223_CR46) 2019; 13
Q Wang (2223_CR38) 2020; 579
DS Perekalin (2223_CR90) 2015; 21
C Lee (2223_CR116) 2017; 8
F Jia (2223_CR68) 2021; 13
S Jirawatnotai (2223_CR11) 2011; 474
S Maher (2223_CR64) 2006; 71
M Drag (2223_CR77) 2010; 9
L Luo (2223_CR145) 2018; 29
W Saeed (2223_CR67) 2017; 3
H Hu (2223_CR104) 2018; 8
R Yazdian-Robati (2223_CR120) 2019; 45
S Rahimi (2223_CR108) 2022; 189
ALB Seynhaeve (2223_CR147) 2020; 163–164
ZM Lu (2223_CR87) 2008; 33
M Yang (2223_CR94) 2020; 6
K Song (2223_CR146) 2023; 356
B Tang (2223_CR47) 2022; 18
A Fomitcheva-Khartchenko (2223_CR29) 2022; 8
G Gajski (2223_CR58) 2016; 110
Y Cui (2223_CR101) 2020; 10
Z Liu (2223_CR150) 2023; 10
Z Maani (2223_CR118) 2023; 1272
S Thangudu (2223_CR102) 2022; 20
RJ Vandebriel (2223_CR39) 2022; 12
HR Lan (2223_CR105) 2023; 21
J Gao (2223_CR126) 2021; 11
N Asthana (2223_CR72) 2004; 279
E Han (2223_CR8) 2023; 28
JE Huh (2223_CR30) 2012; 75
J Ding (2223_CR88) 2012; 28
C Huang (2223_CR107) 2013; 7
S Lv (2223_CR42) 2021; 277
D Sun (2223_CR113) 2015; 7
M Curcio (2223_CR123) 2022; 12
P Hubert (2223_CR143) 2021; 9
H Jung (2223_CR89) 2022; 26
M Ashrafizadeh (2223_CR130) 2022; 351
R Schreiber (2223_CR49) 2018; 596
CL Ownby (2223_CR66) 1997; 35
SH Rajabnejad (2223_CR119) 2018; 44
H Cao (2223_CR132) 2018; 18
M Obeidat (2223_CR17) 2023; 23
X Li (2223_CR53) 2022; 56
S Maher (2223_CR133) 2007; 24
J Zhang (2223_CR138) 2023; 8
B Cheng (2223_CR140) 2020; 12
Y Kim (2223_CR76) 2019; 11
C Ding (2223_CR139) 2022; 16
Y Zhou (2223_CR6) 2020; 7
MC Shin (2223_CR111) 2016; 33
ER Mohammed (2223_CR10) 2022; 37
JM Cole (2223_CR54) 2021; 13
Y Dai (2223_CR122) 2023; 21
Q Zhao (2223_CR41) 2022; 12
MT Lee (2223_CR60) 2013; 110
T Xu (2223_CR27) 2017; 14
H Li (2223_CR103) 2022; 15
A Hartmann (2223_CR84) 2016; 11
M Sylvestre (2223_CR151) 2021; 331
NY Kwon (2223_CR1) 2021; 71
J Wang (2223_CR135) 2020; 323
Y Guo (2223_CR9) 2023; 6
M Chen (2223_CR36) 2022; 19
FG Avci (2223_CR3) 2018; 8
I Rady (2223_CR18) 2017; 402
A Bahreyni (2223_CR121) 2023; 163
M Motiei (2223_CR125) 2021; 128
HR Jia (2223_CR124) 2018; 7
References_xml – volume: 38
  start-page: 1551
  issue: 7
  year: 2016
  ident: 2223_CR2
  publication-title: Clin Ther
  doi: 10.1016/j.clinthera.2016.03.026
– volume: 45
  start-page: 603
  issue: 4
  year: 2019
  ident: 2223_CR120
  publication-title: Drug Dev Ind Pharm
  doi: 10.1080/03639045.2019.1569029
– volume: 19
  start-page: 1
  year: 2020
  ident: 2223_CR32
  publication-title: Integr Cancer Ther
  doi: 10.1177/1534735420944476
– volume: 8
  start-page: 3597
  issue: 13
  year: 2018
  ident: 2223_CR104
  publication-title: Theranostics
  doi: 10.7150/thno.25608
– volume: 12
  start-page: 66
  issue: 2
  year: 2020
  ident: 2223_CR33
  publication-title: Toxins
  doi: 10.3390/toxins12020066
– volume: 24
  start-page: 1346
  issue: 7
  year: 2007
  ident: 2223_CR133
  publication-title: Pharm Res
  doi: 10.1007/s11095-007-9246-z
– volume: 33
  start-page: 2218
  issue: 9
  year: 2016
  ident: 2223_CR111
  publication-title: Pharm Res
  doi: 10.1007/s11095-016-1959-4
– volume: 596
  start-page: 217
  issue: 2
  year: 2018
  ident: 2223_CR49
  publication-title: J Physiol
  doi: 10.1113/JP275175
– volume: 13
  start-page: 16488
  issue: 24
  year: 2023
  ident: 2223_CR129
  publication-title: RSC Adv
  doi: 10.1039/D3RA00866E
– volume: 14
  start-page: 6901
  issue: 6
  year: 2017
  ident: 2223_CR27
  publication-title: Oncol Lett
– volume: 7
  start-page: 691
  issue: 5
  year: 2015
  ident: 2223_CR96
  publication-title: Wiley Interdiscip Rev Nanomed Nanobiotechnol
  doi: 10.1002/wnan.1332
– volume: 23
  start-page: 1004
  issue: 6
  year: 2016
  ident: 2223_CR44
  publication-title: Cell Death Differ
  doi: 10.1038/cdd.2016.35
– volume: 20
  start-page: 1508
  issue: 6
  year: 2019
  ident: 2223_CR141
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms20061508
– volume: 8
  start-page: e2984
  issue: 8
  year: 2017
  ident: 2223_CR40
  publication-title: Cell Death Dis
  doi: 10.1038/cddis.2017.390
– volume: 46
  start-page: 253
  issue: 3
  year: 2018
  ident: 2223_CR85
  publication-title: Allergol Immunopathol
  doi: 10.1016/j.aller.2017.05.003
– volume: 15
  start-page: 1033159
  year: 2022
  ident: 2223_CR103
  publication-title: Front Mol Neurosci
  doi: 10.3389/fnmol.2022.1033159
– volume: 28
  start-page: 173
  issue: 2
  year: 2012
  ident: 2223_CR88
  publication-title: Neurosci Bull
  doi: 10.1007/s12264-012-1213-y
– volume: 37
  start-page: 686
  issue: 1
  year: 2022
  ident: 2223_CR10
  publication-title: J Enzyme Inhib Med Chem
  doi: 10.1080/14756366.2022.2036985
– volume: 213
  start-page: 112384
  year: 2022
  ident: 2223_CR61
  publication-title: Colloids Surf B Biointerfaces
  doi: 10.1016/j.colsurfb.2022.112384
– volume: 20
  start-page: 599
  issue: 2
  year: 2017
  ident: 2223_CR79
  publication-title: J Asia Pac Entomol
  doi: 10.1016/j.aspen.2017.03.023
– volume: 6
  start-page: 1977
  issue: 11
  year: 2020
  ident: 2223_CR92
  publication-title: ACS Cent Sci
  doi: 10.1021/acscentsci.0c00506
– volume: 1272
  start-page: 134160
  year: 2023
  ident: 2223_CR118
  publication-title: J Mol Struct
  doi: 10.1016/j.molstruc.2022.134160
– volume: 11
  start-page: 13069
  issue: 27
  year: 2019
  ident: 2223_CR99
  publication-title: Nanoscale
  doi: 10.1039/C9NR01820D
– volume: 75
  start-page: 1922
  issue: 11
  year: 2012
  ident: 2223_CR30
  publication-title: J Nat Prod
  doi: 10.1021/np300446c
– volume: 10
  start-page: 574
  issue: 1
  year: 2019
  ident: 2223_CR56
  publication-title: Nat Commun
  doi: 10.1038/s41467-019-08538-x
– volume: 33
  start-page: 2085
  issue: 10
  year: 2008
  ident: 2223_CR87
  publication-title: Neurochem Res
  doi: 10.1007/s11064-008-9689-6
– volume: 26
  start-page: 158
  issue: 4
  year: 2022
  ident: 2223_CR89
  publication-title: Anim Cells Syst
  doi: 10.1080/19768354.2022.2099971
– volume: 18
  start-page: 7
  issue: 4
  year: 2015
  ident: 2223_CR74
  publication-title: J Pharmacopuncture
  doi: 10.3831/KPI.2015.18.031
– volume: 14
  start-page: e0224028
  issue: 10
  year: 2019
  ident: 2223_CR24
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0224028
– volume: 18
  start-page: 180
  issue: 1
  year: 2022
  ident: 2223_CR47
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.64654
– volume: 13
  start-page: 55902
  issue: 47
  year: 2021
  ident: 2223_CR128
  publication-title: ACS Appl Mater Interfaces
  doi: 10.1021/acsami.1c17618
– volume: 27
  start-page: 1653
  issue: 5
  year: 2022
  ident: 2223_CR78
  publication-title: Molecules
  doi: 10.3390/molecules27051653
– volume: 189
  start-page: 114467
  year: 2022
  ident: 2223_CR108
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2022.114467
– volume: 355
  start-page: 745
  year: 2023
  ident: 2223_CR148
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2023.02.020
– volume: 35
  start-page: 67
  issue: 1
  year: 1997
  ident: 2223_CR66
  publication-title: Toxicon
  doi: 10.1016/S0041-0101(96)00078-5
– volume: 23
  start-page: 132
  issue: 1
  year: 2023
  ident: 2223_CR17
  publication-title: BMC Complement Med Ther
  doi: 10.1186/s12906-023-03897-x
– volume: 110
  start-page: 56
  year: 2016
  ident: 2223_CR58
  publication-title: Toxicon
  doi: 10.1016/j.toxicon.2015.12.005
– volume: 56
  start-page: 1007
  issue: 6
  year: 2010
  ident: 2223_CR81
  publication-title: Toxicon
  doi: 10.1016/j.toxicon.2010.07.005
– volume: 8
  start-page: 77
  issue: 3
  year: 2018
  ident: 2223_CR3
  publication-title: Biomolecules
  doi: 10.3390/biom8030077
– volume: 387
  start-page: 154
  issue: 1–2
  year: 2010
  ident: 2223_CR134
  publication-title: Int J Pharm
  doi: 10.1016/j.ijpharm.2009.12.022
– volume: 29
  start-page: 1863
  issue: 1
  year: 2022
  ident: 2223_CR15
  publication-title: Drug Deliv
  doi: 10.1080/10717544.2022.2072544
– volume: 47
  start-page: 1160
  issue: 3
  year: 2015
  ident: 2223_CR112
  publication-title: Int J Oncol
  doi: 10.3892/ijo.2015.3078
– volume: 12
  start-page: e727
  issue: 2
  year: 2022
  ident: 2223_CR41
  publication-title: Clin Transl Med
  doi: 10.1002/ctm2.727
– volume: 139
  start-page: 15940
  issue: 44
  year: 2017
  ident: 2223_CR93
  publication-title: J Am Chem Soc
  doi: 10.1021/jacs.7b09224
– volume: 163
  start-page: 114789
  year: 2023
  ident: 2223_CR121
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2023.114789
– volume: 12
  start-page: 16040
  issue: 14
  year: 2020
  ident: 2223_CR97
  publication-title: ACS Appl Mater Interfaces
  doi: 10.1021/acsami.0c00303
– volume: 20
  start-page: 157
  issue: 1
  year: 2022
  ident: 2223_CR102
  publication-title: J Nanobiotechnol
  doi: 10.1186/s12951-022-01355-3
– volume: 579
  start-page: 415
  issue: 7799
  year: 2020
  ident: 2223_CR37
  publication-title: Nature
  doi: 10.1038/s41586-020-2071-9
– volume: 7
  start-page: 147
  issue: 1
  year: 2019
  ident: 2223_CR117
  publication-title: J Immunother Cancer
  doi: 10.1186/s40425-019-0610-4
– volume: 15
  start-page: 2563
  year: 2020
  ident: 2223_CR142
  publication-title: Int J Nanomedicine
  doi: 10.2147/IJN.S243223
– volume: 4
  start-page: 24
  issue: 1
  year: 2020
  ident: 2223_CR115
  publication-title: NPJ Precis Oncol
  doi: 10.1038/s41698-020-00129-0
– volume: 8
  start-page: 54951
  issue: 33
  year: 2017
  ident: 2223_CR116
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.18627
– volume: 21
  start-page: 245
  issue: 1
  year: 2023
  ident: 2223_CR122
  publication-title: J Nanobiotechnology
  doi: 10.1186/s12951-023-02026-7
– volume: 9
  start-page: 690
  issue: 9
  year: 2010
  ident: 2223_CR77
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd3053
– volume: 24
  start-page: 8388
  issue: 9
  year: 2023
  ident: 2223_CR110
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms24098388
– volume: 14
  start-page: 460
  issue: 7
  year: 2022
  ident: 2223_CR5
  publication-title: Toxins
  doi: 10.3390/toxins14070460
– volume: 12
  start-page: 2225
  issue: 9
  year: 2022
  ident: 2223_CR39
  publication-title: Drug Deliv Transl Res
  doi: 10.1007/s13346-022-01206-6
– volume: 32
  start-page: e2002380
  issue: 38
  year: 2020
  ident: 2223_CR45
  publication-title: Adv Mater
  doi: 10.1002/adma.202002380
– volume: 10
  start-page: 1503
  issue: 12
  year: 2021
  ident: 2223_CR149
  publication-title: Antibiotics
  doi: 10.3390/antibiotics10121503
– volume: 11
  start-page: 239
  issue: 5
  year: 2019
  ident: 2223_CR76
  publication-title: Toxins
  doi: 10.3390/toxins11050239
– volume: 279
  start-page: 55042
  issue: 53
  year: 2004
  ident: 2223_CR72
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M408881200
– volume: 6
  start-page: 0052
  year: 2023
  ident: 2223_CR9
  publication-title: Research
  doi: 10.34133/research.0052
– volume: 13
  start-page: 12638
  issue: 11
  year: 2019
  ident: 2223_CR46
  publication-title: ACS Nano
  doi: 10.1021/acsnano.9b04181
– volume: 24
  start-page: 85
  issue: 2
  year: 2022
  ident: 2223_CR35
  publication-title: Cell J
– volume: 14
  start-page: 428
  issue: 7
  year: 2022
  ident: 2223_CR69
  publication-title: Toxins
  doi: 10.3390/toxins14070428
– volume: 12
  start-page: 1473
  issue: 3
  year: 2022
  ident: 2223_CR127
  publication-title: Acta Pharm Sin B
  doi: 10.1016/j.apsb.2021.07.020
– volume: 56
  start-page: 398
  issue: 5–6
  year: 2022
  ident: 2223_CR53
  publication-title: Free Radic Res
  doi: 10.1080/10715762.2022.2131551
– volume: 7
  start-page: e1800380
  issue: 16
  year: 2018
  ident: 2223_CR124
  publication-title: Adv Healthc Mater
  doi: 10.1002/adhm.201800380
– volume: 10
  start-page: 4569
  issue: 5
  year: 2018
  ident: 2223_CR144
  publication-title: ACS Appl Mater Interfaces
  doi: 10.1021/acsami.7b18809
– volume: 28
  start-page: 1087
  issue: 3
  year: 2023
  ident: 2223_CR8
  publication-title: Molecules
  doi: 10.3390/molecules28031087
– volume: 15
  start-page: 4875
  issue: 11
  year: 2023
  ident: 2223_CR14
  publication-title: Aging
– volume: 8
  start-page: e10482
  year: 2023
  ident: 2223_CR138
  publication-title: Bioeng Transl Med
  doi: 10.1002/btm2.10482
– volume: 11
  start-page: e0158235
  issue: 7
  year: 2016
  ident: 2223_CR84
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0158235
– volume: 28
  start-page: e20210067
  year: 2022
  ident: 2223_CR28
  publication-title: J Venom Anim Toxins Incl Trop Dis
– volume: 7
  start-page: 5791
  issue: 7
  year: 2013
  ident: 2223_CR107
  publication-title: ACS Nano
  doi: 10.1021/nn400683s
– volume: 9
  start-page: 541
  year: 2021
  ident: 2223_CR7
  publication-title: Bioact Mater
– volume: 9
  start-page: e47946
  year: 2020
  ident: 2223_CR63
  publication-title: Elife
  doi: 10.7554/eLife.47946
– volume: 356
  start-page: 232
  year: 2023
  ident: 2223_CR146
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2023.03.004
– volume: 116
  start-page: 105329
  year: 2021
  ident: 2223_CR12
  publication-title: Bioorg Chem
  doi: 10.1016/j.bioorg.2021.105329
– volume: 71
  start-page: 209
  issue: 3
  year: 2021
  ident: 2223_CR1
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21660
– volume: 21
  start-page: 247
  issue: 1
  year: 2023
  ident: 2223_CR105
  publication-title: J Nanobiotechnol
  doi: 10.1186/s12951-023-01990-4
– volume: 1548
  start-page: 427
  year: 2017
  ident: 2223_CR70
  publication-title: Methods Mol Biol
  doi: 10.1007/978-1-4939-6737-7_31
– volume: 147
  start-page: 408
  issue: 3
  year: 2010
  ident: 2223_CR98
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2010.07.116
– volume: 250
  start-page: 1131
  issue: 5
  year: 2013
  ident: 2223_CR65
  publication-title: Protoplasma
  doi: 10.1007/s00709-013-0489-8
– volume: 3
  start-page: 111
  issue: 1
  year: 2017
  ident: 2223_CR67
  publication-title: J Nat Prod Resour
– volume: 11
  start-page: 1371
  issue: 8
  year: 2023
  ident: 2223_CR80
  publication-title: Friction
  doi: 10.1007/s40544-022-0710-x
– volume: 474
  start-page: 230
  issue: 7350
  year: 2011
  ident: 2223_CR11
  publication-title: Nature
  doi: 10.1038/nature10155
– volume: 52
  start-page: 102317
  year: 2022
  ident: 2223_CR48
  publication-title: Redox Biol
  doi: 10.1016/j.redox.2022.102317
– volume: 351
  start-page: 50
  year: 2022
  ident: 2223_CR130
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2022.08.001
– volume: 470
  start-page: 305
  issue: 2
  year: 2018
  ident: 2223_CR52
  publication-title: Pflugers Arch
  doi: 10.1007/s00424-017-2065-0
– volume: 308
  start-page: 172
  year: 2019
  ident: 2223_CR131
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2019.07.004
– volume: 285
  start-page: 416
  issue: 3
  year: 2018
  ident: 2223_CR21
  publication-title: FEBS J
  doi: 10.1111/febs.14186
– volume: 8
  start-page: 1019
  issue: 12
  year: 2022
  ident: 2223_CR29
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2022.07.008
– volume: 10
  start-page: 563938
  year: 2020
  ident: 2223_CR101
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.563938
– volume: 13
  start-page: 42533
  issue: 36
  year: 2021
  ident: 2223_CR68
  publication-title: ACS Appl Mater Interfaces
  doi: 10.1021/acsami.1c14285
– volume: 10
  start-page: 247
  issue: 2
  year: 2020
  ident: 2223_CR22
  publication-title: Biomolecules
  doi: 10.3390/biom10020247
– volume: 13
  start-page: 17158
  issue: 15
  year: 2021
  ident: 2223_CR4
  publication-title: ACS Appl Mater Interfaces
  doi: 10.1021/acsami.1c03640
– volume: 10
  start-page: e2204184
  issue: 7
  year: 2023
  ident: 2223_CR150
  publication-title: Adv Sci
  doi: 10.1002/advs.202204184
– volume: 34
  start-page: 159
  issue: 2
  year: 2017
  ident: 2223_CR82
  publication-title: Postepy Dermatol Alergol
  doi: 10.5114/ada.2017.67082
– volume: 14
  start-page: 155
  issue: 1
  year: 2016
  ident: 2223_CR26
  publication-title: J Transl Med
  doi: 10.1186/s12967-016-0910-0
– volume: 110
  start-page: 14243
  issue: 35
  year: 2013
  ident: 2223_CR60
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1307010110
– volume: 21
  start-page: 4923
  issue: 13
  year: 2015
  ident: 2223_CR90
  publication-title: Chemistry
  doi: 10.1002/chem.201406510
– volume: 29
  start-page: 2936
  issue: 9
  year: 2018
  ident: 2223_CR145
  publication-title: Bioconjug Chem
  doi: 10.1021/acs.bioconjchem.8b00352
– volume: 7
  start-page: 1901866
  issue: 5
  year: 2020
  ident: 2223_CR6
  publication-title: Adv Sci
  doi: 10.1002/advs.201901866
– volume: 9
  start-page: e001966
  issue: 3
  year: 2021
  ident: 2223_CR143
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-001966
– volume: 47
  start-page: 1964
  issue: 6
  year: 2008
  ident: 2223_CR34
  publication-title: Hepatology
  doi: 10.1002/hep.22240
– volume: 7
  start-page: 423
  issue: 2
  year: 2015
  ident: 2223_CR113
  publication-title: DLM Toxins
  doi: 10.3390/toxins7020423
– volume: 579
  start-page: 421
  issue: 7799
  year: 2020
  ident: 2223_CR38
  publication-title: Nature
  doi: 10.1038/s41586-020-2079-1
– volume: 71
  start-page: 1289
  issue: 9
  year: 2006
  ident: 2223_CR64
  publication-title: Biochem Pharmacol
  doi: 10.1016/j.bcp.2006.01.012
– volume: 19
  start-page: 3427
  issue: 12
  year: 2018
  ident: 2223_CR13
  publication-title: Asian Pac J Cancer Prev
  doi: 10.31557/APJCP.2018.19.12.3427
– volume: 30
  start-page: 228
  issue: 2
  year: 2019
  ident: 2223_CR51
  publication-title: J Am Soc Nephrol
  doi: 10.1681/ASN.2018010039
– volume: 21
  start-page: 701
  issue: 2
  year: 2020
  ident: 2223_CR100
  publication-title: Biomacromol
  doi: 10.1021/acs.biomac.9b01416
– volume: 13
  start-page: 274
  issue: 2
  year: 2021
  ident: 2223_CR54
  publication-title: Cancers
  doi: 10.3390/cancers13020274
– volume: 19
  start-page: 183
  issue: 1
  year: 2022
  ident: 2223_CR36
  publication-title: J Neuroinflamm
  doi: 10.1186/s12974-022-02547-2
– volume: 12
  start-page: 2851
  issue: 16
  year: 2022
  ident: 2223_CR123
  publication-title: Nanomaterials
  doi: 10.3390/nano12162851
– volume: 14
  start-page: 1178776
  year: 2023
  ident: 2223_CR114
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2023.1178776
– volume: 128
  start-page: 112258
  year: 2021
  ident: 2223_CR125
  publication-title: Mater Sci Eng C Mater Biol Appl
  doi: 10.1016/j.msec.2021.112258
– volume: 18
  start-page: 4762
  issue: 8
  year: 2018
  ident: 2223_CR132
  publication-title: Nano Lett
  doi: 10.1021/acs.nanolett.8b01236
– volume: 6
  start-page: eabc7828
  issue: 40
  year: 2020
  ident: 2223_CR43
  publication-title: Sci Adv
  doi: 10.1126/sciadv.abc7828
– volume: 23
  start-page: 3094
  issue: 6
  year: 2022
  ident: 2223_CR55
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms23063094
– volume: 21
  start-page: 616
  issue: 5
  year: 2016
  ident: 2223_CR83
  publication-title: Molecules
  doi: 10.3390/molecules21050616
– volume: 331
  start-page: 142
  year: 2021
  ident: 2223_CR151
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2021.01.015
– volume: 11
  start-page: 1110
  issue: 1
  year: 2020
  ident: 2223_CR57
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-14906-9
– volume: 13
  start-page: 1001553
  year: 2022
  ident: 2223_CR16
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2022.1001553
– volume: 8
  start-page: e69380
  issue: 7
  year: 2013
  ident: 2223_CR31
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0069380
– volume: 27
  start-page: 135
  issue: 3
  year: 2011
  ident: 2223_CR86
  publication-title: Neurosci Bull
  doi: 10.1007/s12264-011-1018-4
– volume: 6
  start-page: 1973
  issue: 7
  year: 2020
  ident: 2223_CR94
  publication-title: Bioact Mater
– volume: 11
  start-page: 3301
  issue: 7
  year: 2021
  ident: 2223_CR126
  publication-title: Theranostics
  doi: 10.7150/thno.51988
– volume: 52
  start-page: 2011
  issue: 6
  year: 2023
  ident: 2223_CR50
  publication-title: Chem Soc Rev
  doi: 10.1039/D2CS00454B
– volume: 22
  start-page: 738
  issue: 2
  year: 2021
  ident: 2223_CR91
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms22020738
– volume: 20
  start-page: 790
  issue: 7
  year: 2020
  ident: 2223_CR19
  publication-title: Anticancer Agents Med Chem
  doi: 10.2174/1871520620666200211091451
– volume: 15
  start-page: 1407
  issue: 5
  year: 2023
  ident: 2223_CR136
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics15051407
– volume: 534
  start-page: 215615
  year: 2022
  ident: 2223_CR23
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2022.215615
– volume: 277
  start-page: 121076
  year: 2021
  ident: 2223_CR42
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2021.121076
– volume: 16
  start-page: 13513
  issue: 9
  year: 2022
  ident: 2223_CR139
  publication-title: ACS Nano
  doi: 10.1021/acsnano.2c05379
– volume: 22
  start-page: 237
  issue: 4
  year: 2012
  ident: 2223_CR75
  publication-title: J Investig Allergol Clin Immunol
– volume: 71
  start-page: 1655
  issue: 11
  year: 2019
  ident: 2223_CR95
  publication-title: J Pharm Pharmacol
  doi: 10.1111/jphp.13158
– volume: 11
  start-page: 319
  issue: 4
  year: 2017
  ident: 2223_CR73
  publication-title: Int J Hematol Oncol Stem Cell Res
– volume: 402
  start-page: 16
  year: 2017
  ident: 2223_CR18
  publication-title: Cancer Lett
  doi: 10.1016/j.canlet.2017.05.010
– volume: 1202
  start-page: 331
  issue: 2
  year: 1993
  ident: 2223_CR71
  publication-title: Biochim Biophys Acta
  doi: 10.1016/0167-4838(93)90024-L
– volume: 12
  start-page: 582
  issue: 9
  year: 2020
  ident: 2223_CR140
  publication-title: Toxins
  doi: 10.3390/toxins12090582
– volume: 20
  start-page: 323
  issue: 1
  year: 2022
  ident: 2223_CR109
  publication-title: J Nanobiotechnology
  doi: 10.1186/s12951-022-01536-0
– volume: 12
  start-page: e2301087
  year: 2023
  ident: 2223_CR137
  publication-title: Adv Healthc Mater
  doi: 10.1002/adhm.202301087
– volume: 7
  start-page: 1126
  issue: 4
  year: 2015
  ident: 2223_CR25
  publication-title: Toxins
  doi: 10.3390/toxins7041126
– volume: 44
  start-page: 982
  issue: 6
  year: 2018
  ident: 2223_CR119
  publication-title: Drug Dev Ind Pharm
  doi: 10.1080/03639045.2018.1427760
– volume: 323
  start-page: 59
  year: 2020
  ident: 2223_CR135
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2020.04.019
– volume: 9
  start-page: 327
  year: 2022
  ident: 2223_CR20
  publication-title: J Hepatocell Carcinoma
  doi: 10.2147/JHC.S355027
– volume: 277
  start-page: 102118
  year: 2020
  ident: 2223_CR62
  publication-title: Adv Colloid Interface Sci
  doi: 10.1016/j.cis.2020.102118
– volume: 12
  start-page: e160921188997
  issue: 2
  year: 2022
  ident: 2223_CR59
  publication-title: Nat Prod J
– volume: 9
  start-page: 4957
  issue: 5
  year: 2015
  ident: 2223_CR106
  publication-title: ACS Nano
  doi: 10.1021/nn5070259
– volume: 163–164
  start-page: 125
  year: 2020
  ident: 2223_CR147
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2020.02.004
SSID ssj0022424
Score 2.51055
SecondaryResourceType review_article
Snippet As a naturally occurring cytolytic peptide, melittin (MLT) not only exhibits a potent direct tumor cell-killing effect but also possesses various...
Abstract As a naturally occurring cytolytic peptide, melittin (MLT) not only exhibits a potent direct tumor cell-killing effect but also possesses various...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 454
SubjectTerms Allergic reactions
Angiogenesis
Antimicrobial peptides
Antimitotic agents
Antineoplastic agents
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Antitumor activity
Apoptosis
Biotechnology
Bladder cancer
Cancer therapies
Cell cycle
Cell death
Chemical properties
Chemistry
Chemistry and Materials Science
Coagulation
Colorectal cancer
Cyclin-dependent kinases
Cytolytic activity
Dosage and administration
Drug delivery
Drug delivery systems
Drug dosages
Drug resistance
Drugs
Health aspects
Humans
Hypersensitivity
Immunomodulation
Immunomodulators
Immunomodulatory
Kinases
Melitten - chemistry
Melitten - pharmacology
Melitten - therapeutic use
Melittin
Metastasis
Molecular Medicine
Molecular modelling
Multimechanism
Nanoparticles
Nanoparticles - chemistry
Nanotechnology
Neoplasms - drug therapy
Peptides
Peptides - therapeutic use
Pharmaceutical research
Proteins
Review
Side effects
Therapy
Toxicity
Tumor
Tumor necrosis factor-TNF
Tumors
Vascular endothelial growth factor
Vehicles
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9UwEA-yeNCD-G3dVaIIHrRs0yZt4m0VFwVZxC_2FvLysT7YlyfbvkX_e2fatL6uqBdvpZmEdmaSmWFmfiHkScVYaDD1z8F65by2dW5MUDlzLLjCFEH2HXJf3jVHR_L4WL3fuuoLa8IGeOCBcfsiGKYWwpfgX3HrBOibtAyTe4x71t8vXILXMwZTKdTCpoexRUbW-y1YNQFhc4k5SzCIOZ-ZoR6t__czecsoXSyYvJA17Y3R4XVyLXmR9GD4-hvkko83ydUtbMFb5Ds4hLAOTUn-li4jXflTzEjEHG2Xo9FECJlTZRwF75UabNrdrOBpKkB_QbEDBaZii_CyXbW0W9OhfhyWcLAibIYftO1GzInb5PPh60-v3uTpmoXcQvDR5TJUpeNSmBCUqKzlwi54WPCmglDGNaLxspIwFoypgjO-sMYYD4HZomqsB7I7ZCeuo79HqPC1sgUc_8x57uoA3qcqA8R0C-6MMnVG2Mh1bRMGOV6Fcar7WETWepCUBknpXlKaZ-TZNOfbgMDxV-qXKMyJEtGz-xegUzpxVP9LpzLyGFVBIz5GxAKcE7NpW_324wd9AO4y-LR1U2TkaSIKa_gHa1I_A3ACIbVmlHszStjAdj48apxOB0irSwUbqML4OyOPpmGciUVx0a83QCOVKIVUEvh6d1DQ6b8r8DxAfE1G5Ex1Z4yZj8Tl1x5enBW1FA0TGXk-avmv7_oz5-__D87vkisl7lLG8lLukZ3ubOMfkMv2vFu2Zw_7Pf4TvWRT2w
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: SpringerLINK Contemporary 1997-Present
  dbid: RSV
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwEB5BQQIeOMoVKMggJB5oRJzYicNbqahAQhVqoeqb5fVRVupm0SaL4N8zk4umHBK8rdbjKJ7M8Y3mMMCzjPNQUOpfoPeKRW7z2JhQxtzx4BKTBNV2yB29L_b31fFx-aFvCquHavchJdla6latVf6yRs8kMfRNKe-ITi0WF-ESujtF6nhweDSGWdTwMLTH_HbfxAW1k_p_tcdnHNL5YslzGdPWEe3d-L8j3ITrPfBkO52k3IILvtqEK7vDfW-bcO3MaMLb8A3xJL4K62sEajav2MKfUkKjisn1OVaZCiPuvrCOIfhlhnp-1wv8Ndavv2LUwIJbqcN4Xi9q1ixZV36Oj3D4RNSl76xuhpEVd-DT3puPu2_j_paG2GLs0sQqZKkTSpoQSplZK6SdiTATRYaRkCtk4VWmcC0YkwVnfGKNMR7jullWWI9kd2GjWlb-PjDp89Im6D2488LlAcFrmQYMCWfCmdLkEfDhw2nbjzCnmzROdRvKqFx3HNbIYd1yWIsIXox7vnQDPP5K_ZrkYaSk4dvtH8vVie45qmUwvJxJnyLkF9ZJNIHKcso3c-ERv0bwlKRJ03iNiup3Tsy6rvW7wwO9g2gbIXFeJBE874nCEs9gTd8OgZygiVwTyq0JJYqFnS4PQqt7-1PrtET9yyh8j-DJuEw7qaau8ss10qhSplKVCvl6r5Px8dwZAhf8fEUEaiL9E8ZMV6r553Y6OU9yJQsuI9gelODne_2Z8w_-jfwhXE1JjziPU7UFG81q7R_BZfu1mderx61B-AF-01zN
  priority: 102
  providerName: Springer Nature
Title Recent advances in melittin-based nanoparticles for antitumor treatment: from mechanisms to targeted delivery strategies
URI https://link.springer.com/article/10.1186/s12951-023-02223-4
https://www.ncbi.nlm.nih.gov/pubmed/38017537
https://www.proquest.com/docview/2902132184
https://www.proquest.com/docview/2895258986
https://pubmed.ncbi.nlm.nih.gov/PMC10685715
https://doaj.org/article/5fa19b5e281b4cd58808c1584714e112
Volume 21
WOSCitedRecordID wos001109968900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVADU
  databaseName: BioMed Central Open Access Free
  customDbUrl:
  eissn: 1477-3155
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0022424
  issn: 1477-3155
  databaseCode: RBZ
  dateStart: 20030101
  isFulltext: true
  titleUrlDefault: https://www.biomedcentral.com/search/
  providerName: BioMedCentral
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1477-3155
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0022424
  issn: 1477-3155
  databaseCode: DOA
  dateStart: 20030101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1477-3155
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0022424
  issn: 1477-3155
  databaseCode: M~E
  dateStart: 20030101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 1477-3155
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0022424
  issn: 1477-3155
  databaseCode: M7P
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1477-3155
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0022424
  issn: 1477-3155
  databaseCode: 7X7
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Materials Science Database
  customDbUrl:
  eissn: 1477-3155
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0022424
  issn: 1477-3155
  databaseCode: KB.
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/materialsscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 1477-3155
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0022424
  issn: 1477-3155
  databaseCode: BENPR
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 1477-3155
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0022424
  issn: 1477-3155
  databaseCode: PIMPY
  dateStart: 20090101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVAVX
  databaseName: SpringerLINK Contemporary 1997-Present
  customDbUrl:
  eissn: 1477-3155
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0022424
  issn: 1477-3155
  databaseCode: RSV
  dateStart: 20031201
  isFulltext: true
  titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22
  providerName: Springer Nature
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1Nb9Mw1GIbBzjw_REYlUFIHCAsTuzE4YJWtIkJqKoOpu5kuf4YldZkNC2Cf8-z63TLELtwidq8Zyu2n9-H34cRepkRYgvn-qcgvWKaqzyW0pYx0cTqRCaW-wy5o8_FYMDH43IYDtyaEFbZ8kTPqHWt3Bn5TlpCj5kzSN6f_YjdrVHOuxqu0NhAW65KQuZD94Zrg8ulPrSJMjzfaUC2MTCeU-e5BLEY044w8jX7_-bMF0TT5bDJS75TL5L2b__vYO6gW0EZxbsr6rmLrpnqHrp5oUThffQL9Er4EBxiBRo8rfDMnDrHRhU7EahxJSuwvEOAHQYlGEuX-7ucwa91HPs77BJZoKnLNJ42swYvarwKQ4cuNPQIe-o3bhZt6YoH6Nv-3tcPH-NwW0OswIZZxNxmqaacSWtLlilFmZpQO6FFBhaRLlhheMYBZqXMrJYmUVJKA_bdJCuUAbSHaLOqK_MYYWbyUiUgRYg2VOcWlNgytWAaTqiWpcwjRNplEyqUMnc3apwKb9LwXKyWWsBSC7_Ugkbo9brN2aqQx5XYfUcNa0xXhNu_qOcnIsyoYFaScsJMCqo_VZoBK-SKOL8zoQb02Ai9cLQkXJmNysXxnMhl04iDw5HYBa0bVOO8SCL0KiDZGsagZEiLgJlwlbk6mNsdTOADqgtuaU0EPtSIc0KL0PM12LV0sXWVqZeAw0uWMl5ymNdHKwpfjzsDBQaWr4gQ79B-Z2K6kGr63VcpJ0nOWUFYhN602-T8u_4980-uHsZTdCN1G5iQOOXbaHMxX5pn6Lr6uZg28x7aKMaFf_Ie2urvDYajnj9lgeen_tueZw8AGR58GR7Dv9Hh0R_8_Gro
linkProvider ProQuest
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1R3ZbtQw0CoFCXjgPgIFDALxAFHjxE4cJITKUXXVpapoQX0zXscuK3WTZbML9Kf4RmZytSmib33gLVqPrcxkPMfORcjTiDGXYOifg_byeWxiX2uX-ixjLgt04GRVIfdlmGxtyb29dHuJ_G5rYTCtspWJlaDOCoP_ka-GKZwYoUPyZvrdx6lRGF1tR2jUbLFpD3-Cy1a-HryH7_ssDNc_7L7b8JupAr4BW3vuSxeFGZdCO5eKyBguzIi7EU8isNyzRCRWRhLWnNaRy7QNjNbagh8yihJjAQzOPUfOgxkRyipVcLtz8LDUoi3MkfFqCbpUgLMeYqQU1LDPe8qvmhHwtyY4pgpPpmmeiNVWKnD96v9GvGvkSmNs07X6dlwnSza_QS4fa8F4k_wCuxkQp00uREnHOZ3YAwzc5D6q-IzmOi-mbQIhBSOfaqxtXkzgqcvTf0WxUAe2YiX1uJyUdF7QOs0ejsjgRJAZh7Sct605bpHPZ4L6bbKcF7m9S6iwcWoC0JIsszyLHRjpaejA9R3xTKc69ghr2USZplU7Tgw5UJXLJmNVs5YC1lIVaynukRfdnmndqORU6LfIfR0kNhmvfihm-6qhqBJOs3QkbAiuDTeZAFEvDcO4OuMW7HSPPEHeVdhGJMc8pX29KEs12Pmk1sCrANM_TgKPPG-AXAE4GN2UfQAlsPNYD3KlBwlyzvSXW95WjZwt1RFje-Rxt4w7MXcwt8UCYGQqQiFTCXS9U9-oDu8IDDT4fIlHZO-u9QjTX8nH36ou7CyIpUiY8MjL9loevde_KX_vdDQekYsbux-HajjY2rxPLoUoPBjzQ7lCluezhX1ALpgf83E5e1iJHkq-nvV1_QOuDMME
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwELagIAoPHOUKFDAIqQ8QNU7sxOGtFFZUVKuKQtU3y-ujXambrTZZBP-emVxsyiEh3qJ4bMWTGc98msOEvEwY8xmG_jlYr5CnJg219nnILPM20pGXdYXc0X42Hsvj4_xgpYq_znbvQpJNTQN2aSqq7XPrGxWX6XYJVkoADI4xBgkGLuSXyRWOlwYhXj886iEXFj90pTK_nTcwR3XX_l_P5hXjdDFx8kL0tDZKo1v_v53b5GbrkNKdRoLukEuu2CDru909cBvkxkrLwrvkG_iZsDBtcwdKOi3ozJ1hoKMI0SRaWugCkHibcEfBKaYaa4GXM3jq89rfUCxsgalYeTwtZyWt5rRJS4clLKwIOvadllXXyuIe-TJ6_3n3Q9je3hAawDRVKH0SWy6F9j4XiTFcmAn3E54lgJBsJjInEwljXuvEW-0io7V2gPcmSWYckN0na8W8cA8JFS7NTQRWhVnHberBqc1jD1Bxwq3OdRoQ1v1EZdrW5njDxpmqIY5MVcNhBRxWNYcVD8irfs5509jjr9RvUTZ6SmzKXb-YL05Uy1ElvGb5RLgYoAA3VsDRKA3DODTjDvzagLxAyVLYdqPAvJ4TvSxLtXf4Se2AFw6ucppFAdlqifwc9mB0WyYBnMBOXQPKzQEliIUZDncCrNpzqVRxDnqZIKwPyPN-GGdirl3h5kugkbmIhcwl8PVBI-_9vhNwaOD3ZQGRA00YMGY4UkxP667lLEqlyJgIyOtOIX5-1585_-jfyJ-RawfvRmp_b_zxMbkeo0oxFsZyk6xVi6V7Qq6ar9W0XDytz4kfMX9olQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recent+advances+in+melittin-based+nanoparticles+for+antitumor+treatment%3A+from+mechanisms+to+targeted+delivery+strategies&rft.jtitle=Journal+of+nanobiotechnology&rft.au=Yu%2C+Xiang&rft.au=Jia%2C+Siyu&rft.au=Yu%2C+Shi&rft.au=Chen%2C+Yaohui&rft.date=2023-11-28&rft.eissn=1477-3155&rft.volume=21&rft.issue=1&rft.spage=454&rft_id=info:doi/10.1186%2Fs12951-023-02223-4&rft_id=info%3Apmid%2F38017537&rft.externalDocID=38017537
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-3155&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-3155&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-3155&client=summon